Document is current
Any future updates will be listed below
-
Authors
Lau, Tang Ching
Chang, Dong-Gune
Chen, Chung-Hwan
Huang, Shuang
Lau, Edith M. C.
Law, Sheung-Wai
Lee, Young-Kyun
Tolman, Cae
Canals, Laura
Yeo, See-Hwee
Ebeling, Peter R.
-
Funding
Funding for this research was provided by:
Amgen Foundation
- License Information
-
More Information
Article History
Received: 10 December 2025
Accepted: 16 May 2026
First Online: 17 June 2026
Declarations
:
: Shuang Huang, Cae Tolman, Laura Canals are employees and stockholders of Amgen Inc. See-Hwee Yeo is an employee of Real World Solutions, IQVIA Solutions Asia at time of study. Peter R. Ebeling received research funding and honoraria from Amgen. Other authors report no other potential conflicts of interest. The study medications (denosumab and alendronate) were not reimbursed by Sponsor (Amgen Inc.) or IQVIA.
: The study was conducted in accordance with the Declaration of Helsinki, and the study protocol received ethical approval from the Institutional Review Board of all local sites.
: Informed consent was obtained from all individual participants included in the study.
